According to a company release, the highlight of this quarter is the introduction of as many as seven products including line extensions. In two of these products, namely Eurepa, an anti-diabetic drug and Toroxx, an analgesic for the treatment of acute and chronic pain, Torrent has been the first company to develop and market them. The launch of Topcef (Cefixime, an antibiotic) was another significant addition to the product portfolio of Torrent Pharmaceuticals. This spate of new introductions, the fruit of the sustained efforts by Torrent in R&D and market development, is expected to lay the foundation for higher growth rates in the future.

the company has also applied for a US patent for certain promising compounds and is actively exploring options for acquisition of brands and companies both in the domestic and international arena.